U.S. Markets closed

FDA rejects Merck drug, threatening millions in payments to Afferent investors

·3 min read
FDA rejects Merck drug, threatening millions in payments to Afferent investors
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Merck promised to pay out $750 million if the Peninsula biotech's drugs passed certain clinical and commercial milestones.